洛铂联合伊立替康二线治疗小细胞肺癌的临床研究

目的 观察洛铂联合伊立替康二线治疗复治性晚期小细胞肺癌（SCLC）的疗效和安全性。方法 洛铂联合伊立替康治疗26 例复发或进展SCLC，洛铂 35mg／m² d₁，伊立替康200mg／m² d₁，21d为1周期。2个周期评价疗效，1个周期评价毒副反应，并随访总生存时间（OS）和无进展生存时间（PFS）。结果 26例患者均可评价疗效，CR 2例，PR 8例， 总有效率（RR）为42.3％；SD 6例，PD 9例。中位PFS为4.3个月，中位OS为7.1个月。主要毒副反应为血液学毒性和消化道反应， 其中3、4级白细胞减少发生率为53.8％（14／26），3～4级血小板减少发生率为46.2％（12／26）；1～3级恶心呕吐发生率为61.5％（16／26），无4级发生； 1～2级腹泻发生率为30.8％（8／26），无3～4级发生。全组无1例因毒性相关死亡。结论 洛铂联合伊立替康作为二线方案治疗复治性晚期SCLC有较好的疗效， 毒副反应可以耐受。

Clinical observation of combined chemotherapy of lobaplatin and irinotecan in the second-line treatment of relapsed advanced small cell lung cancer

Objective To observe the efficacy and safety of chemotherapy consisted of lobaplatin and irinotecan for patients with advanced small cell lung cancer （SCLC）. Methods Twenty-six patients of recurrence or progression SCLC were treated with lohaplatin joint irinotecan-based therapy, lobaplatin 35 mg/m2 d1 , irinotecan 200 mg/mz d1. Every 21 days was a cycle. Therapeutic effect was evaluated after 2 cycles and adverse reaction was recorded after 1 cycle. Overall survival time （OS） and no progress survival time （PFS） were followed-up. Results Twenty-six patients were evaluatable for response, in which 2 achieved complete reponse and 8 partial response, and the objective response rate was 42. 3%. Six patients got stable, and nine patients progressed. The median PFS of 26 patients was 4. 3 months and the median OS was 7.1 months. The main side effects were hematology toxicity and gastrointestinal re- action. Grade 3-4 leukopenia rate was 53.8 % （14/26）, grade 3-4 thrombocytopenia rate was 46. 2% （12/26 ） , grade 1-3 nausea and vomiting rate was 61.5% （16/26） , and grade 1-2 diarrhea rate was 30. 8% （8/26）. No toxic related death was observed. Conclusion The combination of lobaplatin and irinotecan as second-line chemotherapy is highly active and tolerable in patients with relapsed SCLC.